Prediction of cardiovascular (CV) complications represents the Achilles' heel of end-stage renal disease. Surrogate markers of endothelial dysfunction have been advocated as predictors of CV risk in this cohort of patients. We have recently adapted a noninvasive laser Doppler flowmetry (LDF) functional testing of endothelium-dependent microvascular reactivity and demonstrated that end-stage renal disease patients are characterized by profound alterations in thermal hyperemic responsiveness. We hypothesized that such functional assessment of the cutaneous microcirculation may offer a valid, noninvasive test of the severity of endothelial dysfunction and CV risk. To test this hypothesis, we performed a cross-sectional study, in which we compared LDF measurements to conventional risk factors, and performed a pilot longitudinal study. LDF studies were performed in 70 patients and 33 controls. Framingham and Cardiorisk scores were near equivalent for low-risk patients, but more divergent as risk increased. C reactive protein (CRP) levels and LDF parameters (amplitude of thermal hyperemia (TH), area under the curve of TH) showed significant abnormality in high-risk vs low-risk patients calculated using either Framingham or Cardiorisk scores. Patients who had abnormal LDF parameters showed increased CV mortality, however, had similar risk assessments (Framingham, Cardiorisk, CRP, and homocysteine) to those with unimpaired LDF tracings. In conclusion, LDF parameters of microvascular reactivity offer a sensitive characterization of endothelial dysfunction, which may improve CV risk assessment through incorporation into the Framingham or Cardiorisk algorithm.
Prediction of cardiovascular (CV) complications represents the Achilles' heel of end-stage renal disease. Surrogate markers of endothelial dysfunction have been advocated as predictors of CV risk in this cohort of patients. We have recently adapted a noninvasive laser Doppler flowmetry (LDF) functional testing of endothelium-dependent microvascular reactivity and demonstrated that end-stage renal disease patients are characterized by profound alterations in thermal hyperemic responsiveness. We hypothesized that such functional assessment of the cutaneous microcirculation may offer a valid, noninvasive test of the severity of endothelial dysfunction and CV risk. To test this hypothesis, we performed a cross-sectional study, in which we compared LDF measurements to conventional risk factors, and performed a pilot longitudinal study. LDF studies were performed in 70 patients and 33 controls. Framingham and Cardiorisk scores were near equivalent for low-risk patients, but more divergent as risk increased. C reactive protein (CRP) levels and LDF parameters (amplitude of thermal hyperemia (TH), area under the curve of TH) showed significant abnormality in high-risk vs low-risk patients calculated using either Framingham or Cardiorisk scores. Patients who had abnormal LDF parameters showed increased CV mortality, however, had similar risk assessments (Framingham, Cardiorisk, CRP, and homocysteine) to those with unimpaired LDF tracings. In conclusion, LDF parameters of microvascular reactivity offer a sensitive characterization of endothelial dysfunction, which may improve CV risk assessment through incorporation into the Framingham or Cardiorisk algorithm.
Epidemiological evidence has firmly established the link between end-stage renal disease (ESRD) and cardiovascular (CV) disease. 1, 2 Mechanistically this linkage depends on widespread microvascular endothelial cell dysfunction (ECD) in patients with ESRD leading inexorably to CV disease. Early detection of ECD in ESRD is therefore central to determining patient risk. Until recently, such detection has depended on algorithms using surrogate markers of ECD. Examples of surrogate markers include elevated levels of C reactive protein (CRP), homocysteine, circulating selectins, plasminogen activator-1, and asymmetric dimethylarginine. [3] [4] [5] [6] [7] While useful, markers often fail to provide direct evidence of microvascular ECD but rather furnish indirect correlative information.
For this reason, we have adopted laser Doppler flowmetry (LDF) techniques of noninvasive assessment of cutaneous blood flow. Cutaneous microvascular dysfunction participates in ECD in a variety of disease states including hypertension, insulin resistance, cardiac allograft vasculopathy, and advanced diabetic retinopathy. LDF measurements correlate well with angiographically demonstrated coronary artery disease (CAD) (in review Stewart et al.
8
).
Using an array of parameters obtained from reactive hyperemic and local thermal hyperemic challenges, we have recently obtained data showing abnormal co-clustering of parameters of LDF in ESRD patients with clinically evident CAD and diabetes mellitus (DM). 8 We have therefore proposed that such functional assessments of the cutaneous microcirculation may offer a valid, noninvasive test of the severity of endothelial dysfunction and CV risk. To test this hypothesis, we performed a cross-sectional study in which we compared LDF measurements to conventional risk factors. Specifically, the Framingham risk assessment score has been proposed for predicting the CV risk in the general population. 4, 9 In addition, we compared LDF data to a recently modified algorithm, Cardiorisk, 10 which has been advocated as a more accurate estimator of CV risk, though neither has been tested in ESRD. Our current data indicate that LDF indices closely correlate with the predictive risk of CV complications in this particularly vulnerable cohort of patients. Also, we performed a pilot limited longitudinal study of this group of patients, the results of which suggested that LDF abnormalities characteristic of ECD were more sensitive predictors of ensuing CV disease than other tested predictors.
RESULTS

Comparison of Framingham and Cardiorisk 10-year risk assessment
We performed a comparative analysis of CV risk in the cohort of ESRD patients, which were examined using LDF. As shown in Figure 1 , the majority of our patients, and in particular those at the lower end of the risk spectrum, scored similarly using Framingham and Cardiorisk (10-year) scoring systems. However, for patients receiving higher risk scores, there was an increased disparity between these two methods, with a tendency towards the higher risk scores obtained using the Cardiorisk algorithm than the Framingham scoring system.
Comparison of risk assessment and surrogate markers of CV risk
Elevated CRP and hyperhomocysteinemia have been proposed as independent risk factors. 4 Therefore, we compared the levels of CRP and homocysteine with the calculated risk obtained using each of these two methods. Patients were ranked according to their CV risk and separated about the median into low-and high-risk groups for each set of risk criterion. The high-risk group had elevated CRP values, which did not reach significance by Framingham criteria but were significant (Po0.05, Figure 2 ) using Cardiorisk (10-year) system. CRP also differed between risk groups when plotted against the Cardiorisk cumulative lifetime risk (0.7670.2 low-risk vs 2.1770.9 high-risk, Po0.05, data not shown). Homocysteine levels were not different between high-and low-risk groups using Framingham or Cardiorisk. However, only four of the studied patients, all in the 'lowrisk' group, had normal homocysteine levels.
LDF as a predictor of CV risk
Data were compared between high-and low-risk groups as outlined above for 10-year risk scores. Postocclusive reactive hyperemia data did not correlate with risk using either Framingham or Cardiorisk. However, thermal hyperemia (TH) parameters were well correlated with the calculated CV risk. (Figure 3 ). Similar findings appeared using Cardiorisk (Figure 4 Figure 5 . Additionally, the area under the TH curve was compared with risk using linear regression over the entire risk spectrum and correlated significantly with the Framingham risk score (P ¼ 0.01) but not with Cardiorisk ( Figure 6 ). The lifetime risk score using Cardiorisk did not correlate with any of the collected LDF data.
LDF data were also analyzed for correlation with homocysteine and CRP levels. Linear regression failed to demonstrate a statistically significant relation between any one of the laser Doppler flow parameters and either of these markers. Values at lower portion of risk spectrum were almost equivalent when calculated using either method. At the higher portion of risk spectrum, there was a tendency for Cardiorisk to produce a higher estimate than Framingham risk assessment. Results are shown as 10-year risk (%). High-risk patients (above the median) had prolonged times to reach the thermal peaks and the nadir although the differences were not significant. High-risk patients had significantly diminished amplitudes for the (g) first heat peak, (h) heat nadir, and (i) second heat peak.
The combined predictive ability of the surrogate markers and LDF data was assessed by receiver operating characteristic (ROC) curves using mROC, 7 calculating the linear combination that maximizes the area under the ROC curve for each 2-and 3-parameter combinations, as well as for the combination of all of the parameters. The largest area under ROC curve for both Cardiorisk (10-year) and Framingham was found by combining all of the collected data ( Figure 7 ). The area under the curve was 0.802 for both Cardiorisk and Framingham with 95% confidence intervals (CI) of 0.5-0.810 (Cardiorisk score) and 0.5-0.816 (Framingham score).
Ten-year risk using LDF and Cardiorisk. The strongest predictors of actual risk using Cardiorisk þ LDF were CRP and area under the heat curve that, when combined, had an area under ROC curve of 0.748 (CI 0.609-0.84). A number of additional parameters, when combined with CRP and area under the heat curve, offered modest improvements to area under the ROC curve up to 0.764 (CI 0.614-0.848).
Ten-year risk using LDF and Framingham. Using Framingham þ LDF system to assess risk, the best predictors were CRP, amplitude of second heat peak and area under the heat curve in combination. The single best pairing to predict risk was amplitude of second heat peak and area under the heat curve that had a ROC area of 0.725 (CI 0.58-0.82). Combining this pair with numerous third parameters modestly improved the ROC area up to 0.751 (CI 0.596-0.837).
Lifetime risk. The area under ROC curve for the lifetime risk (Cardiorisk system) was smaller than using 10-year risk (0.758 with CI of 0.5-0.747). The parameters with the greatest contribution to predicting lifelong risk were the area under the curve for reactive and TH, which combined for an area of 0.706 (CI 0.554-0.806).
Subgroup analysis and patient prognosis
We previously demonstrated that abnormalities in LDF parameters cosegregated with ESRD, CAD, and DM. 8 Of particular interest was that a large number of ESRD patients with no known CAD or DM had LDF findings similar to those of patients that did have CV complications. We therefore examined whether the LDF parameters correlated with increased risk using Framingham, Cardiorisk, CRP, or homocysteine. The patients were grouped relative to the median for area under the TH curve, as this parameter had the strongest relationship with risk as outlined above. (The same result was obtained when mean values were used.) As seen in Figure 8 , the patients with abnormal LDF parameters had higher risk scores using both Framingham and Cardiorisk, although neither result was statistically significant. CRP levels were somewhat lower in this low perfusion group, while homocysteine levels were equal, and neither of these parameters showed statistically significant differences between the groups. We next compared patients grouped by increasing expected severity of endothelial dysfunction into three groups: those with neither CAD nor DM, those with CAD or DM, and those with both CAD and DM. Results are shown ( Figure 9 ) for their risk assessment, surrogate markers, and LDF parameters. Framingham risk increased with severity, Cardiorisk had an unexpectedly low score for the CAD þ DM group. CRP levels in the CAD þ DM were elevated compared to the other two groups although not significantly. Homocysteine levels were not different between the groups. On the other hand, LDF parameters of ECD demonstrated significant and progressive differences, as shown in Figure 8 . ESRD patients who died due to CV causes invariably had abnormal LDF parameters 1-2 years earlier, particularly the amplitude of the first and second thermal peaks, which was two-to three-fold lower than in the surviving population (Figure 10 ), despite the fact that all other surrogate markers were comparable in both groups. Furthermore, Mann-Whitney analysis showed that the nadir, the amplitude of the postocclusive hyperemic response and the postocclusive recruitment of capillaries into the hypemic response contributed to the outcomes. Specifically, (1) CV mortality was associated with the decreased amplitude of the first thermal peak and the nadir (significant at P ¼ 0.041 and 0.045, respectively), (2) development of congestive heart failure was associated with the same parameters (significant at P ¼ 0.017 and 0.038, respectively), and (3) development of coronary heart disease was associated with the postocclusive recruitment of dermal capillaries (significant at P ¼ 0.016).
DISCUSSION
Our data demonstrate co-segregation of abnormal LDF parameters with calculated increased CV risk using either Framingham or Cardiorisk indices in ESRD patients. We The subset of ESRD patients with no known history of CAD or DM was grouped according to the results of their LDF study. The patients whose area under the TH curve was lower than the median were grouped as 'low perfusion'. Those patients above the median were termed 'high perfusion'. Low perfusion patients had somewhat increased risk assessments using both the (a) Cardiorisk and (b) Framingham criteria, although the differences were not significant. No statistically significant differences in (c) CRP levels or (b) homocysteine levels existed between low-and high-perfusion groups. have also shown that LDF parameters of endothelial function contain information, which is independent of risk indices. In addition, when combined with risk scores enhances our ability to predict future CV risk or death in those ESRD patients. LDF parameters of microvascular ECD are of prognostic value in a significant proportion of ESRD patients free of known manifestations of CV disease. However, many findings while consistent failed to reach statistical significance underscoring the pilot and relatively weakly powered nature of the present study and pointing towards the need for a larger better powered study, which is currently underway.
One interesting negative finding was relatively poor coclustering of CRP and homocysteine levels with the patients at higher CV risk. While there was no linear relationship, there was some tendency for the higher risk population to have elevated CRP levels. Also, homocysteine levels in our ESRD patients were almost uniformly elevated, and therefore no correlation between these values and the risk assessment scores was noted. Future studies will use the high-sensitivity CRP, which should better reveal such a relationship with LDF markers and with overall risk.
The question of defining high-risk in ESRD deserves special consideration. The consensus cutoff at 10% has been widely used with Framingham score, 4 but its applicability to ESRD patients has not been demonstrated. Cardiorisk scores are numerically higher than those obtained with Framingham system. High risk cutoff remains controversial especially for ESRD patients In the current study, we used several approaches to convert risk assessment to binary parameters: (a) applied 10% risk cutoff for both; (b) estimated an average Cardiorisk cutoff point of 13% that corresponds to the 10% consensus Framingham risk; (c) used the median value for each risk assessment as a cutoff point. While the level of significance varied between these methods, the trends observed between the high-and low-risk groups followed the same patterns regardless of the method.
Having adapted these Framingham and Cardiorisk risk estimators to our patient population facilitated comparison with LDF data. The high-risk population was characterized by a markedly diminished local thermal hyperemic response. This was evident at all measured data points: initial heat peak, heat nadir, and second heat peak. Statistically, the differences between the high-and low-risk groups were more significant using the Framingham criteria than the Cardiorisk system. The area under the curve for 30 min of heating was a particularly robust LDF measure of CV risk and is also computationally robust being relatively insensitive to artifact and timing.
Combining measured LDF parameters with Framingham or Cardiorisk estimators to form ROC curves improved the ability to predict CV risk in our ESRD population. Framingham or Cardiorisk systems were equivalent, and the ability of each system to predict CV morbidity and mortality was enhanced by the addition of LDF parameters.
One limitation of the study was that it focused exclusively on ESRD patients. ECD is present in a large percentage of patients with ESRD. This may limit the importance of the additional information provided by our noninvasive technology. ESRD is implicitly defined by the need for dialysis and corresponds to K/DOQI stage 5(2). If ECD is nearuniversal in this cohort, then prediction has a limited value. For that reason, we will extend our patient base to include a subset of chronic kidney disease patients without end-stage disease corresponding to K/DOQI stages 3 and 4.
In conclusion, this study has provided several important insights into CV risk assessment. First, Cardiorisk scoring system predicts a higher risk than Framingham, although the predictive value of each, based on ROC curve, is equivalent in ESRD. Second, surrogate markers of risk, such as CRP, correlate with increased risk within the ESRD population and should be incorporated in future risk assessment criteria. Homocysteine, despite its usefulness in the general population, appears to be more uniformly elevated in ESRD, and is thus not useful in predicting risk. Other markers of risk are currently under investigation and will be included in future studies. Finally, laser Doppler flow study has been shown to be a valid marker a CV risk: abnormal LDF parameters co-cluster with the presence or absence of ESRD, diabetes, and known coronary disease, 8 and have now been shown to correlate with several predictors of CV risk. An important aspect of the study has emerged during our subgroup analysis of ESRD patients with no known coronary disease or diabetes. One-half of these patients exhibit aberrant LDF parameters similar to those seen in ESRD patients with known CAD and/or DM. Despite this distinction in LDF parameters, all other risk assessment methods utilized in this study failed to indicate a difference between these groups, whereas LDF abnormalities are associated with significantly increased CV mortality. Abnormal LDF parameters are sensitive indicators of an increased CV risk, which, in combination with conventional risk systems, provide enhanced prognostic information concerning CV disease in ESRD. Further diagnostic and prognostic validation of this noninvasive test of microvascular endothelial dysfunction will require a longitudinal prospective study of ESRD patients.
MATERIALS AND METHODS Subjects and experimental outline
The study had a two-pronged design. First, we compared indices of LDF with standard Framingham and Cardiorisk CV risk assessment systems. Second, we performed a longitudinal prospective cohort study on all subjects over up to 2 years follow-up.
We studied 70 male and female ESRD patients between the ages of 24 and 86 with renal failure, who were attending our dialysis unit. Patients examined had no surgical procedures on the limb used for investigation. Subjects had no food intake for at least 2 h, did not take their morning medications and smokers were asked to abstain from smoking for at least 3 h prior to the testing. Exclusion criteria were as follows: psoriasis, peripheral neuropathy, liver failure, neoplastic disease, Cushing's syndrome, collagen vascular disease, dermatological problems, chronic angioedema, or lymphedema, uncontrolled hyperthyroidism, chronic substance abuse, or any condition precluding the subjects completion of the protocol. The Committee for the Protection of Human Subjects (IRB) at New York Medical College approved this study, and all examined individuals read and signed an informed consent.
Controls were healthy male and female subjects, who were agematched to ESRD patients. Control subjects were enrolled with exclusion criteria similar to ESRD patients except that controls had no ESRD, chronic kidney disease, CV disease, or diabetes. Neither cases nor controls were taking neurally active or vasoactive medications on the morning of study.
Testing was performed prior to dialysis in a temperaturecontrolled room kept at 241C with a relative humidity of 40%. All tests were performed while subjects sat in a comfortable armchair. Following a 30-min acclimatization period, we measured blood pressure and heart rate, and subjects were acclimated to the laser equipment, monitoring equipment, and environment. The arm selected for investigations had no graft or fistula. It was positioned at heart level and gently immobilized using a vacuum pillow containing polyurethane beads, which moulds to the shape of the arm (Germa, Sweden). Two areas of the volar aspect of the forearm were chosen: one a 2 Â 2 cm 2 site for laser-Doppler perfusion imaging (Perimed PeriScan PIM II, Stockholm, Sweden), with each scan taking approximately ten seconds; a second site spaced approximately 6 cm from the scanning site was used to continuously measure skin blood perfusion using a laser-Doppler perfusion monitor (LDPM) with single-point LDF probes (Perimed Periflux System 5000, Stockholm, Sweden). Continuous LDPM employed coherent laser light at a wavelength of 780 nm, which was sampled at a rate of 32 samples per second. LDF was measured in arbitrary perfusion units (PFU). Sampled LDF was interfaced to a personal computer through an A/D converter (DATAQ) using PeriSoft data acquisition software. LDPM data were electronically readjusted such that baseline flow fell on the Y-axis for perfusion units and changes in LDF were measured thereafter. We applied two types of challenges to the cutaneous microcirculation: an arterial occlusion cuff and local hyperthermia and measured LDPM during postobstructive reactive hyperemia (PORH) and TH, respectively (Figure 11 ).
PORH
Following the acclimatization period, baseline LDPM and laserDoppler perfusion imaging of the forearm were recorded. An occlusion cuff placed around the upper arm was inflated to a pressure 15 mm Hg above the systolic pressure for 4 min. The absence of cutaneous flow was documented by the LDF. PORH response (pay-back response) upon release of arterial occlusion was recorded until full recovery to basal level. The payback response was quantified by measuring the area under the PORH curve with respect to the baseline (defined as zero). At the peak of payback response, laser-Doppler perfusion imaging of the same volar forearm 2 Â 2 cm 2 area was performed. Data analysis was performed using PeriSoft software (Perimed). We measured peak flow (PFU), time to peak flow (s), and area under the curve (PFUs).
Local TH. Local heating of nonglabrous skin such as the forearm evokes vasodilation that is mediated by local neurogenic reflexes and is almost entirely nitric oxide dependent. [11] [12] [13] [14] The LDPM probe was heated to 431C over a 2-min period. LaserDoppler flow was measured over the next 30 min to record flow patterns characterized by an initial peak, followed by a nadir, and finally rising to a second peak that continues as a sustained plateau. Kellogg, Johnson and co-workers 12 and Minson et al 14 showed that the dilator response to local heating is related to nitric oxide, which plays a major role in the sustained cutaneous vasodilation (i.e. the secondary plateau) of prolonged heating. Nitric oxide synthase inhibitors blunt both measured heat peaks but have a more pronounced effect on the second peak and plateau.
Cross-sectional risk assessment and statistical analyses The 10-year CV risk was assessed using both the Framingham criteria (age, low-density lipoprotein, high-density lipoprotein, blood pressure, history of diabetes, and history of smoking), and a newer web based computer program, Cardiorisk 10 based on the Framingham criteria, except for substituting total cholesterol for low-density lipoprotein. Additional criteria include prior history PORH measurements included (a) amplitude and (b) time to peak as well as the (c) area under the curve. Thermal hyperemia measurements included (d-f) amplitudes and (g-i) times to first heat peak, heat nadir and second heat peak, respectively. Additionally, the area under the curve for the first 30 min of heating was measured.
of atrial fibrillation, left ventricular hypertrophy and known CV disease. Data were grouped according to the 10-year risk assessment (expressed as % risk) using each set of criteria. The patients were then divided relative to the median into high-and low-risk groups.
Values for each group are expressed as mean7s.e. Mann-Whitney tests were used to assess significance. Correlations between the continuous variables and risk scores were estimated using Kendal's t for nonparametric distribution. ROC curves were performed using mROC 15 to assess the ability of the combined data to predict CV risk.
Longitudinal risk assessment and statistical analyses At 2 years after an initial LDF study, CV mortality and surrogate end points including development of coronary heart disease, myocardial infarction, cerebrovascular accidents, peripheral arterial disease, and congestive heart failure were assessed based on the clinical data. Nonparametric Mann-Whitney test was used to establish the significance of the contribution of each LDF parameter to the individual outcome.
